Harvard Bioscience, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, -8.6% a year (statements).
US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt less cash at the end of FY2025 (statements); negative means more cash than debt.
What today's price assumes
A market value of $38 M means free cash flow growing 0.7% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.
Revenue grew -8.6% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | -13.6% | -11.1% | -8.6% | -6.1% | -3.6% |
|---|---|---|---|---|---|
| 8.15% | -92% | -77% | -58% | -35% | -7% |
| 9.15% | -101% | -88% | -72% | -52% | -29% |
| 10.15% | -107% | -96% | -82% | -65% | -45% |
| 11.15% | -112% | -102% | -90% | -76% | -58% |
| 12.15% | -116% | -107% | -96% | -84% | -69% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Harvard Bioscience, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Medical Instruments
Multiples of its companies with a market value at most 60 days old, times Harvard Bioscience, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Harvard Bioscience, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.0× / 3.5× / 6.6× | 0.4× | revenue $87 M | $170 M to $574 M | 23 |
| Price to book | 2.0× / 4.4× / 6.6× | 2.7× | book equity $14 M | $27 M to $91 M | 23 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
Harvard Bioscience, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to sales
0.4×Now above its median of 0.4×; range 0.2× to 3.5× over 27 months.
Price to book
2.7×Now above its median of 1.2×, in the top quarter of its range; range 0.3× to 22.1× over 27 months.
as of Oct 26, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 26, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $87 M | $-57 M | $7 M | $1 M | $5 M | $27 M | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $94 M | $-12 M | $1 M | $3 M | $-1 M | $33 M | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $112 M | $-3 M | $14 M | $2 M | $12 M | $33 M | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $113 M | $-10 M | $1 M | $2 M | $-0 M | $42 M | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $119 M | $-0 M | $1 M | $1 M | $0 M | $41 M | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $102 M | $-8 M | $9 M | $1 M | $8 M | $40 M | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $38 M on Oct 26, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.